Literature DB >> 27509251

Evaluation of Sexual Risk Behavior Among Study Participants in the TDF2 PrEP Study Among Heterosexual Adults in Botswana.

Deborah A Gust1, Fatma Soud, Felicia P Hardnett, Charles K Malotte, Charles Rose, Poloko Kebaabetswe, Lebogang Makgekgenene, Faith Henderson, Lynn Paxton, Tebogo Segolodi, Peter H Kilmarx.   

Abstract

OBJECTIVE: Among participants of a clinical trial to test the efficacy of tenofovir/emtricitabine in protecting heterosexual men and women living in Botswana from HIV infection, the aim was to determine (1) if sexual risk behavior, specifically condomless sex acts and number of sex partners, changed over time, (2) factors associated with condomless sex acts and number of sex partners, and (3) the effect of participant treatment arm perception on risk behavior to address the possibility of risk compensation.
METHODS: A longitudinal modeling of rates of risk behaviors was used to determine if the rate of condomless sex acts (#acts/person) and rate of sex partners (#partners/person) changed over time and which factors were associated with behavior change.
RESULTS: One thousand two hundred participants were analyzed over 1 year. There was a 25% decrease in the rate of sex partners among participants sexually active in the last 30 days. The rate of reported condomless sex acts was greater for males [rate ratio (RR) = 1.34; confidence interval (CI): 1.07 to 1.67] and participants whose sexual debut in years was ≤15 years of age (RR = 1.65; CI: 1.14 to 2.38) and 16-17 (RR = 1.68; CI: 1.22 to 2.31) compared with those ≥20 years. Rate of reported sex partners was greater for males (RR = 3.67; CI: 2.86 to 4.71) and participants whose age at sexual debut in years was ≤15 (RR = 2.92; CI: 2.01 to 4.22) and 16-17 (RR = 2.34; CI: 1.69 to 3.24) compared with those ≥20. There was no effect of participant treatment arm perception on risk behavior.
CONCLUSIONS: Our study of preexposure prophylaxis to prevent HIV infection found no evidence of risk compensation which may have been due to participants' motivations to reduce their risk behaviors and risk-reduction counseling.

Entities:  

Mesh:

Year:  2016        PMID: 27509251      PMCID: PMC6066668          DOI: 10.1097/QAI.0000000000001143

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  44 in total

1.  Medication adherence: tailoring the analysis to the data.

Authors:  Parya Saberi; Mallory O Johnson; Charles E McCulloch; Eric Vittinghoff; Torsten B Neilands
Journal:  AIDS Behav       Date:  2011-10

Review 2.  What is the place of pre-exposure prophylaxis in HIV prevention?

Authors:  Jeroen De Man; Robert Colebunders; Eric Florence; Marie Laga; Christopher Kenyon
Journal:  AIDS Rev       Date:  2013 Apr-Jun       Impact factor: 2.500

3.  Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Authors:  Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

4.  Keeping adolescent orphans in school to prevent human immunodeficiency virus infection: evidence from a randomized controlled trial in Kenya.

Authors:  Hyunsan Cho; Denise D Hallfors; Isabella I Mbai; Janet Itindi; Benson W Milimo; Carolyn T Halpern; Bonita J Iritani
Journal:  J Adolesc Health       Date:  2011-02-18       Impact factor: 5.012

5.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

7.  HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial.

Authors:  Bradford N Bartholow; Susan Buchbinder; Connie Celum; Vamshidar Goli; Beryl Koblin; Michael Para; Michael Marmor; Richard M Novak; Kenneth Mayer; Catherine Creticos; Patti Orozco-Cronin; Vladimir Popovic; Timothy D Mastro
Journal:  J Acquir Immune Defic Syndr       Date:  2005-05-01       Impact factor: 3.731

8.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?

Authors:  Richard Hayes; Deborah Watson-Jones; Connie Celum; Janneke van de Wijgert; Judith Wasserheit
Journal:  AIDS       Date:  2010-10       Impact factor: 4.177

10.  Food insecurity and sexual risk in an HIV endemic community in Uganda.

Authors:  Cari L Miller; David R Bangsberg; David M Tuller; Jude Senkungu; Annet Kawuma; Edward A Frongillo; Sheri D Weiser
Journal:  AIDS Behav       Date:  2011-10
View more
  4 in total

1.  How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP.

Authors:  Victoria Pilkington; Andrew Hill; Sophie Hughes; Nneka Nwokolo; Anton Pozniak
Journal:  J Virus Erad       Date:  2018-10-01

2.  Acceptability of pre-exposure prophylaxis for HIV prevention: facilitators, barriers and impact on sexual risk behaviors among men who have sex with men in Benin.

Authors:  Carin Ahouada; Souleymane Diabaté; Myrto Mondor; Septime Hessou; Fernand A Guédou; Luc Béhanzin; Georges Batona; Ndeye Ndiagna Gning; D Marcel Zannou; Michel Alary
Journal:  BMC Public Health       Date:  2020-08-20       Impact factor: 3.295

3.  Sexual Behaviours and Practices before and after Phase I/II HIV Vaccine Trial: A Qualitative Study among Volunteers in Dar es Salaam Tanzania.

Authors:  Masunga K Iseselo; Edith A M Tarimo; Eric Sandstrom; Asli Kulane
Journal:  Int J Environ Res Public Health       Date:  2020-10-01       Impact factor: 3.390

4.  Trends in Reported Sexual Behavior and Y-Chromosomal DNA Detection Among Female Sex Workers in the Senegal Preexposure Prophylaxis Demonstration Project.

Authors:  D Allen Roberts; Stephen E Hawes; Mame D Bousso Bao; Anna Julienne Ndiaye; Daouda Gueye; Dana N Raugi; Moustapha Mane; Aminata Mboup; Ousmane Diouf; Fatima Jones; Coumba Toure Kane; Moussa Sarr; Souleymane Mboup; Geoffrey S Gottlieb
Journal:  Sex Transm Dis       Date:  2020-05       Impact factor: 3.868

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.